Alluvi, previously BI 4744, presents a promising development in obesity care. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide targets demonstrates impressive effectiveness in https://socialistener.com/story7609297/alluvi-a-detailed-examination-into-retatrutide-s-prospects